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Objective: We evaluated the current clinical experience of temporary inferior vena cava (IVC) filter placement and its
related complications.
Methods: From January 2000 to December 2005, we enrolled 33 patients (8 men and 25 women) who underwent
percutaneous insertion of a temporary IVC filter in the Department of Vascular Surgery of Tokyo University Hospital.
Deep vein thrombosis (DVT) was proven in 78.8% of the patients. The indications for filter insertion were contraindi-
cation to anticoagulation therapy (9.1%), thrombolytic therapy (12.1%), perioperative prophylactic implantation
(84.8%), pregnancy with DVT (3.0%), and prophylactic implantation in the absence of DVT (15.2%). A Neuhaus Protect
was used in 13 patients, and an Antheor was used in 20 patients.
Results: The mean  SD duration of filter placement was 10.6  7.0 days. There was no case of pulmonary embolism
during filter protection and retraction. Filter thrombosis (capture of thrombus) was observed in four patients (12.1%),
who then received additional thrombolytic therapy. Thrombi were dissolved by thrombolysis in three, one of whom had
replacement with a permanent filter. The thrombus was not dissolved in one patient and was removed under venotomy
at the insertion site. Major filter-related complications occurred in nine patients (27.3%), including filter dislocation in
four patients (12.1%), catheter fracture in three (9.1%), and catheter-related infection in one (3.0%). In a patient with
giant ovarian cancer, the IVCwas nearly occluded with massive thrombus around the filter 2 days after operation, and the
vena cava was then ligated under open laparotomy. No patients died during filter protection and retraction.
Conclusions: Temporary IVC filters were effective for the prevention of fatal pulmonary embolism. However, our
experience of a high incidence of complications related to temporary filters suggests that this device has limited indications
and supports the need for innovative design of temporary filters. ( J Vasc Surg 2006;44:620-4.)Anticoagulation therapy has been the standard treatment
for patients with deep vein thrombosis (DVT) and pulmonary
embolism.1-5 Permanent inferior vena cava (IVC) filters have
been in clinical use since 19676 and have gained acceptance
for the prevention of pulmonary embolism arising from
DVT of the lower extremity. A randomized controlled
study in Europe indicated that a permanent IVC filter
decreased the incidence of short-term pulmonary embo-
lism but increased the long-term incidence of recurrent
DVT.7 Previous studies showed that permanent IVC filters
were associated with increased risk of complications such as
IVC thrombosis,8 recurrent venous thromboembolism,7
thrombophlebitis, and venous stasis disease.9,10
Temporary IVC filters, connected to the outside through
a tethering catheter, are designed to avoid the long-term
adverse outcomes of permanent filters and are used in
Europe and Japan. The Food and Drug Administration has
not yet approved them for use in the United States. A
retrievable filter can be used as a temporary or as a perma-
nent filter, whereas a temporary filter is used only as a
temporary protection device against pulmonary embolism.
The indications for insertion of a temporary IVC filter
are not well established. Because no data are available from
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620prospective, randomized controlled studies, the use of tem-
porary IVC filters is still controversial.11,12 In this study, we
reviewed the clinical experience of temporary IVC filter
insertion at our institution, especially with regard to its
complications.
METHODS
From January 2000 to December 2005, we enrolled 33
patients (8 men and 25 women) who underwent percuta-
neous insertion of a temporary IVC filter. The procedures
were performed in the Department of Vascular Surgery of
TokyoUniversity Hospital. The patients’ characteristics are
listed in Table I. The mean  SD age at the time of filter
insertion was 47.8  13.1 years (range, 17 to 81 years).
DVT was evaluated by duplex scanning or computed to-
mography (CT), and pulmonary embolism was evaluated
by CT or pulmonary ventilation/perfusion scan. At the
time of filter implantation, 26 patients (78.8%) had proven
DVT. DVT was present up to the inferior vena cava in 4
patients, the iliac vein in 9, the femoral vein in 6, the
popliteal vein in 3, and the calf vein in 4. Pulmonary
embolism was detected in 12 of these patients before filter
insertion. We examined thrombophilia and all coagulation
parameters, including protein C, protein S, antithrombin
III, lupus anticoagulant antibodies, and anticardiolipin an-
tibodies.
Indication for filter insertion. Filters were inserted
for a variety of indications, and informed consent was
obtained for all filter placements.
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three patients (9.1%) with DVT and intracranial bleeding, a
temporary IVC filter was inserted because of a transient
contraindication to anticoagulation therapy related to a risk
of bleeding.
Thrombolytic therapy. In four patients (12.1%) with
acute DVT (the IVC in 2 patients, the iliac vein in 1, and
the calf vein in 1) and pulmonary embolism, systemic
thrombolytic therapy using urokinase was performed under
protection with a temporary IVC filter to prevent recurrent
pulmonary embolism.
Perioperative implantation. Perioperative insertion
was performed in 28 patients (84.8%). These patients in-
cluded one with renal cell carcinoma associated with renal
vein thrombosis and five with prophylactic implantation in
the absence of DVT as mentioned below. All of these filters
were inserted preoperatively.
Pregnancy associated with DVT. One pregnant pa-
tient (3.0%) who developed DVT during the last trimester
of pregnancy received a temporary IVC filter before
delivery.
Prophylactic implantation in absence of DVT. Five
filters (15.2%) were placed in the absence of DVT before or
during a high-risk situation and during a temporary contra-
indication to full anticoagulation. These filters were all
inserted perioperatively.
All filters were inserted percutaneously through a
sheath via the internal jugular vein, subclavian vein, or
femoral vein. We used a Neuhaus Protect (Toray Medical,
Tokyo, Japan) in 13 patients and a Antheor (Boston Scien-
tific, Watertown, Mass) in 20 patients as a temporary IVC
filter (Fig 1, A and B).
Anticoagulation therapy was administered during filter
placement in all patients in whom it was not contraindi-
cated. We administered intravenous dose-adjusted heparin
to maintain an activated partial thromboplastin time at 1.5
to 2 times the control value. In perioperative cases, heparin
anticoagulant therapy was stopped for at least 6 hours
before the operation and was restarted when the risk of
bleeding had decreased.
We used CT to examine the entrapment of thrombi in
the filter 5 to 7 days after insertion and re-examined this by
vena cavography before explantation. The filter was re-
moved if there was no capture of large thrombi detected
that could develop into pulmonary embolism.When a large
Table I. Patient characteristics
Number of patients 33
Age  SD (range), years 47.8  13.1 (17-81)
Sex
Male 8
Female 25
Deep vein thrombosis 26 (78.8%)
Pulmonary embolism 12 (36.4%)
Malignant disease 14 (42.4%)
Thrombophilia 11 (33.3%)thrombus was detected in the filter, we performed throm-bolytic therapy using catheter-directed administration of
urokinase in cases in which it was not contraindicated.
All patients were followed-up as outpatients for at least
6 months after removal of the filter. We examined the early
outcome and complications resulting from temporary IVC
filter placement.
RESULTS
Outcome. The temporary IVC filters were placed in
the infrarenal IVC in 31 patients and in the suprarenal IVC
in two. The mean  SD duration of filter placement was
10.6  7 days. Eleven patients had thrombophilia, includ-
ing eight with protein S deficiency, two with both anticar-
diolipin antibodies and lupus anticoagulant antibodies, and
one with anticardiolipin antibodies only.
A large thrombus was captured in the filter in four
patients (12.1%) (Table II), and we performed catheter-
directed thrombolytic therapy using a continuous infusion
of urokinase. The thrombus was dissolved in three patients,
and in one of these patients the temporary IVC filter was
replaced with a permanent filter. The thrombus did not
dissolve in one patient and was captured rigidly, so the
thrombus inside the filter was pulled back outside together
with the catheter through a small venotomy in the jugular
vein in the insertion site without protection.
There was no case of pulmonary embolism during filter
protection and retraction.
Complications. Nomajor problems occurred with fil-
Fig 1. A, Neuhaus Protect filter. B, Antheor filter.
Table II. Outcome
Duration of
placement
10.67.0 days
Filter thrombosis 4 (12.1%) 3 resolved by catheter-directed
thrombolytic therapy;
1 removed under venotomy at
the insertion site
Pulmonary
embolism
0 During filter protection and
retractionter insertion, including bleeding. One patient who under-
, Neu
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plained of dysesthesia at the insertion site after filter
retraction. Nine patients (27.2%) experienced major and
minor complications problems during filter protection and
retraction (Table III).
IVC thrombosis developed from the iliac vein to the
proximal side of the filter in a patient with large ovarian
cancer 2 days after operation despite anticoagulation ther-
apy, and the vena cava was nearly occluded with massive
thrombus. Although catheter-directed thrombolytic ther-
apy using urokinase was performed, the thrombus was not
dissolved and the vena cava remained occluded. Because it
was impossible to explant the temporary filter in this situa-
tion, the vena cava was ligated at the infrarenal level prox-
imal to the large thrombus and then the catheter was cut
and explanted under open laparotomy.
Major dislocation of the catheter by more than one
vertebral body occurred in four patients (12.1%); one was
in the right atrium (Fig 2), one was in the suprarenal IVC,
and two were in the iliac vein. All of these filters were
inserted preoperatively, and filter dislocation was detected
after operation in all cases. These filters were removed
without adverse sequelae.
Infection related to the catheter occurred in one patient
(3.0%) with endometriosis before operation. The catheter
was explanted and the operation postponed because of
catheter-related fever. Three months later, the scheduled
operation was uneventfully performed under protection
with a temporary filter.
Fracture of the catheter was observed in three patients
(9.1%); two with a Neuhaus Protect filter and one with an
Antheor. The fracture was observed in the shaft of the
central catheter in the Neuhaus Protect and at the connec-
tion site between the main catheter and side port in the
Antheor. In these cases, the temporary IVC filter was
replaced with another one without further complications.
Complications such as fatal pulmonary embolism, hem-
orrhage at the insertion site, or retroperitoneal bleeding
were not observed. In addition, no patient had a fatal
complication related to implantation of the temporary fil-
ter. During the follow-up period, neither pulmonary em-
bolism nor other filter-related complications were observed
Table III. Complications during filter placement
Complication Age Sex DVT extent Filte
IVC thrombosis 50 F Calf vein N
Filter dislocation 55 F Iliac vein A
44 F Calf vein A
81 F Iliac vein N
38 M Femoral vein N
Equipment fracture 37 F No DVT N
35 M IVC N
72 M IVC A
Catheter infection 32 F No DVT A
DVT, Deep vein thrombosis; IVC, inferior vena cava; M, male; F, female; Nafter filter retraction.DISCUSSION
The only randomized, controlled trial regarding per-
manent IVC filters has been reported by Decousus et al.7
This report indicated that in high-risk patients with proxi-
mal DVT, the initial beneficial effect of an IVC filter
together with anticoagulants for the prevention of pulmo-
nary embolism was counterbalanced by an excess of recur-
rent DVT, without any difference in mortality. Therefore,
only absolute contraindications and documented failure of
anticoagulation therapy in patients with acute venous
thromboembolism represent obvious and widely accepted
indications for IVC interruption.13
A temporary IVC filter can be left in place for a short
term to cover a high-risk period for venous thromboembo-
lism. The indwell time for the temporary filters we used is
Fig 2. Image from a patient with giant ovarian cancer in whom
the temporary filter was inserted in a suprarenal IVC preopera-
tively. This vena cavogram shows the filter migration to the atrium
after operation. Arrowhead shows filter in the atrium.
Associated disease Comments
Ovarian cancer IVC was ligated under open laparotomy
Cholecystolithiasis Common iliac vein
Ovarian cancer Common iliac vein
Ovarian cancer Right atrium
Bone fracture Suprarenal IVC
Pregnancy Shaft of central catheter
None Shaft of central catheter
Colon cancer Connection site of side port
Endometriosis Catheter was explanted
haus Protect; A, Antheor.rup to 2 weeks, as recommended by the manufacturers,
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a Tempofilter (B. Braun, Melsungen, Germany), is longer.
They are designed and tailored to avoid the disadvantage of
permanent systems, such as perforation, penetration, and
caval occlusion, and to provide comparable protection
against pulmonary embolism.9 Several studies have demon-
strated equal effectiveness of permanent and temporary
filters in clot capture.14,15 Temporary IVC filters were
inserted in younger patients, in whom implantation of a
permanent filter should be avoided. Indeed, the average
age of the patients in the present study was 47.8 years.
Despite theoretical advantages of a temporary IVC
filter, the effectiveness of temporary filters is still very con-
troversial. The main points of criticism are the handling of
thrombi captured in the filter before explantation, the
danger of filter explantation under endothelialization with
prolonged implantation,16 dislocation of the filter or cath-
eter during filter placement, and the lack of clearly defined
indications for filter insertion.
Most of the patients in the present study had proven
DVT before filter insertion. In cases of perioperative pro-
phylactic insertion, a temporary filter is generally implanted
until adequate ambulation or a candidate for anticoagula-
tion prophylaxis, but there are no criteria for the duration
of filter placement. Endothelialization has been shown to
cause explantation problems after 12 days,17 and the risk of
endothelialization increases the longer the filter remains in
place. In fact, we experienced many cases in which the
duration of placement had to be extended because of
residual DVT.
A high rate of thrombus capture may lead to the
problem of thrombi caught in the filter, which are detected
on pre-explantation CT or cavography. The rate of 12.1%
in our study is comparable with the previous report of
16%.12 The decision whether to cautiously pull back the
filter or to perform additional thrombolytic treatment is
made according to the thrombus size and general status of
the patient with respect to previous pulmonary embolism.
In general, thrombi 1 cm in diameter are able to be
retracted with the filter.
Several options can be used to overcome the problem
with larger thrombi. Although additional thrombolysis can be
performed to dissolve thrombi in the filter, thrombolytic
therapy is generally contraindicated or should be performed
using low-dose urokinase perioperatively. An alternative strat-
egy to implant a second filter—temporary, retrievable, or
permanent—can be helpful in these situations. However,
because a temporary IVC filter must be explanted, it is
always difficult to make the optimal decision in this con-
flicting situation. In the present study, thrombi were found
in the filter in 12.1% of patients, and they were all in
patients with DVT; however, we have no evidence that all
of these arose from peripheral thrombosis.
Filter dislocation occurred in 12.1% of patients. Lorch
et al14 reported that the rate of dislocation was 4.8% for
temporary filters, whereas that in the present study was
higher. The explanation for this result is that the number of
patients was small, and further, most of our patients wereperioperative or ambulant cases. Although dislocation
within a few centimeters along the vena cava is probably not
significant, migration into other anatomic regions or tilting
may result in additional complications, including pulmo-
nary embolism.
A previous study revealed the problem of the tethering
catheter shaft of a Tempofilter.18 Crimping of the tethering
shaft caused cephalic migration of the filter into the right
atrium. The catheter of the temporary filters used at our
institution is stiffer than the Tempofilter and is hard to
buckle, whereas dislocation of the catheter itself often arises
from loosening of the fixation of the insertion site because
of the stiffness of the catheter itself. Adequate fixation of
the catheter is important, whereas filter dislocation might
be inevitable except in patients on absolute bed rest.
We inserted most of the temporary filters through the
jugular approach. The femoral approach is related to cath-
eter infection and dislocation, and this approach is impos-
sible if thrombus extends up to the iliac vein or vena cava.
On the other hand, Linsenmaier et al19 stated that filters
should be introduced through the right common femoral vein
whenever possible because introduction through the jugular
or brachial vein is associated with a high rate of complications,
including upper vein and central vein thrombosis. Another
reason to avoid the jugular approach is that captured
thrombi can become a serious problem. Pulling back the
device through the right heart creates the risk of iatrogenic
pulmonary embolism.20 Our impression is that both ap-
proaches have some disadvantages whenever we use this
type of temporary IVC filter.
The temporary IVC filter was replaced with a perma-
nent filter in one case. In cases like this, implantation of a
retrievable-optional filter that can be used as a temporary
or, if necessary, as a permanent filter would be beneficial.
These devices are implanted in a manner similar to that for
a permanent filter and retrieved through a new venous
access with a snare, such as the Gunther Tulip filter (Cook,
Bloomington, Ind),21 or they remain connected to a cath-
eter that is fixed subcutaneously, such as the Tempofilter.22
Definite indications for the placement of a temporary
IVC filter have not been established. Linsenmaier et al17
advocated the following indications for a temporary IVC
filter: the existence of DVT and a temporary contraindica-
tion for anticoagulation, recurrent pulmonary embolism
despite adequate anticoagulation therapy, high risk of pul-
monary embolism in cases of severe trauma and high peri-
operative risk, and other prophylactic purposes.
Although temporary filters have been extensively used in
Europe, particularly during thrombolytic treatment of DVT;
the use of such filters during thrombolysis has been ques-
tioned because favorable outcomes have occurred when
thrombolysis has been performed without filter protection, 23
and temporary IVC filters do not seem to decrease the risk of
a fatal pulmonary embolism under ultra-high-dose streptoki-
nase thrombolytic therapy.12 Moreover, the results obtained
with temporary filters for other indications have not been as
good as expected.11,12 Because there are no data available
from prospective, randomized controlled studies, the use of
JOURNAL OF VASCULAR SURGERY
September 2006624 Miyahara et altemporary IVC filters is still controversial. However, as we
broaden the indications for IVC filter placement, particu-
larly for prophylactic filters, it is also our responsibility to
monitor the indications for filter placement and the effec-
tiveness of using temporary filters. In the present study,
there was no case of fatal pulmonary embolism and no
patient died of a filter-related complication.
CONCLUSION
The concept of a temporary IVC filter is reasonable in
specific high-risk situations, but the indication for insertion
has to be defined further. Randomized, controlled trials are
needed to investigate the benefits, adverse effects, and
effectiveness of temporary IVC filters. Temporary IVC
filters are widely used especially in Japan, because the
insertion procedure is easy. However, because temporary
IVC filter insertion is not a treatment but merely a prophy-
lactic procedure to prevent pulmonary embolism, the rela-
tively high incidence of filter-related complications is not
acceptable. These data regarding various complications re-
lated to temporary filters suggest that this device has limited
indications in the clinical setting. Further, the design of this
type of temporary IVC filter should be tailored for safer
handling or the concept should be radically modified. Re-
trievable optional filters are a recent strategy potentially
offering a better solution and a reasonable alternative to
temporary IVC filters, if the retrieval procedure is easy to
perform and the rate of filter-related complications is suffi-
ciently low.
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